| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 32 | 2026 | 480 | 5.560 |
Why?
|
| Simian Immunodeficiency Virus | 23 | 2024 | 100 | 3.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 23 | 2023 | 495 | 2.610 |
Why?
|
| HIV Infections | 25 | 2026 | 2041 | 2.420 |
Why?
|
| Virus Replication | 25 | 2026 | 599 | 2.090 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 18 | 2024 | 77 | 1.680 |
Why?
|
| Single-Chain Antibodies | 3 | 2023 | 43 | 1.420 |
Why?
|
| Anti-HIV Agents | 5 | 2025 | 353 | 1.200 |
Why?
|
| HIV Antibodies | 6 | 2023 | 69 | 1.050 |
Why?
|
| Host-Pathogen Interactions | 4 | 2019 | 260 | 0.930 |
Why?
|
| Macaca nemestrina | 13 | 2013 | 16 | 0.900 |
Why?
|
| Deoxyadenosines | 2 | 2024 | 11 | 0.890 |
Why?
|
| Lectins, C-Type | 5 | 2007 | 69 | 0.760 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 124 | 0.750 |
Why?
|
| Cell Adhesion Molecules | 5 | 2007 | 227 | 0.710 |
Why?
|
| Cell Line | 21 | 2023 | 2592 | 0.710 |
Why?
|
| Dendritic Cells | 5 | 2010 | 437 | 0.660 |
Why?
|
| Receptors, Cell Surface | 5 | 2007 | 432 | 0.660 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 11 | 0.640 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2023 | 359 | 0.600 |
Why?
|
| GPI-Linked Proteins | 3 | 2018 | 105 | 0.590 |
Why?
|
| Virus Latency | 3 | 2026 | 63 | 0.580 |
Why?
|
| Proviruses | 2 | 2026 | 19 | 0.580 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 218 | 0.570 |
Why?
|
| Viral Tropism | 3 | 2018 | 48 | 0.560 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1702 | 0.550 |
Why?
|
| HIV | 2 | 2016 | 178 | 0.540 |
Why?
|
| Prostate | 3 | 2020 | 415 | 0.530 |
Why?
|
| Antigens, CD | 5 | 2015 | 418 | 0.480 |
Why?
|
| Animals | 46 | 2026 | 34218 | 0.480 |
Why?
|
| RNA, Viral | 5 | 2020 | 512 | 0.470 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 358 | 0.470 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 2019 | 37 | 0.470 |
Why?
|
| Virus Internalization | 5 | 2018 | 59 | 0.460 |
Why?
|
| Polymerase Chain Reaction | 6 | 2026 | 1489 | 0.460 |
Why?
|
| Receptors, CCR5 | 5 | 2016 | 31 | 0.440 |
Why?
|
| Macaca | 9 | 2023 | 60 | 0.430 |
Why?
|
| Human T-lymphotropic virus 1 | 5 | 1995 | 64 | 0.420 |
Why?
|
| Genetic Variation | 8 | 2008 | 1565 | 0.410 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 222 | 0.400 |
Why?
|
| Lymphocyte Activation | 6 | 2018 | 632 | 0.390 |
Why?
|
| Macrophages | 6 | 2026 | 662 | 0.390 |
Why?
|
| Virulence Factors | 2 | 2012 | 180 | 0.390 |
Why?
|
| Cell Cycle | 1 | 2015 | 598 | 0.380 |
Why?
|
| Viruses | 2 | 2024 | 118 | 0.370 |
Why?
|
| Xenotropic murine leukemia virus-related virus | 1 | 2012 | 2 | 0.370 |
Why?
|
| Transduction, Genetic | 4 | 2024 | 279 | 0.370 |
Why?
|
| Drug Resistance, Viral | 4 | 2024 | 57 | 0.360 |
Why?
|
| Molecular Sequence Data | 15 | 2011 | 3535 | 0.350 |
Why?
|
| Interferon-alpha | 1 | 2013 | 241 | 0.350 |
Why?
|
| Humans | 65 | 2026 | 131852 | 0.350 |
Why?
|
| Gene Products, vif | 1 | 2011 | 7 | 0.340 |
Why?
|
| Viral Load | 5 | 2016 | 406 | 0.340 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 5 | 0.340 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 10 | 0.340 |
Why?
|
| Antibodies, Viral | 10 | 2024 | 1172 | 0.330 |
Why?
|
| Recombination, Genetic | 2 | 2011 | 423 | 0.330 |
Why?
|
| Immunotherapy | 1 | 2016 | 763 | 0.330 |
Why?
|
| Genetic Vectors | 4 | 2024 | 907 | 0.330 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 131 | 0.310 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 228 | 0.290 |
Why?
|
| Antibodies, Neutralizing | 7 | 2023 | 520 | 0.280 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2024 | 17 | 0.280 |
Why?
|
| Hepatitis C | 1 | 2012 | 390 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2024 | 33 | 0.270 |
Why?
|
| Amino Acid Sequence | 11 | 2010 | 2422 | 0.270 |
Why?
|
| Zika Virus | 2 | 2020 | 155 | 0.270 |
Why?
|
| Glycosylphosphatidylinositols | 4 | 2016 | 16 | 0.250 |
Why?
|
| Cells, Cultured | 12 | 2018 | 2949 | 0.250 |
Why?
|
| Alleles | 2 | 2010 | 1708 | 0.250 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2007 | 300 | 0.240 |
Why?
|
| Sirtuin 2 | 1 | 2026 | 13 | 0.240 |
Why?
|
| Tenofovir | 1 | 2025 | 25 | 0.240 |
Why?
|
| Foreign-Body Reaction | 1 | 2025 | 16 | 0.240 |
Why?
|
| Lentivirus | 2 | 2016 | 81 | 0.230 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2023 | 405 | 0.230 |
Why?
|
| Adenine | 1 | 2025 | 123 | 0.220 |
Why?
|
| Immunity, Innate | 3 | 2020 | 411 | 0.220 |
Why?
|
| Lentivirus Infections | 1 | 2024 | 3 | 0.210 |
Why?
|
| Lamivudine | 1 | 2024 | 29 | 0.210 |
Why?
|
| Inflammasomes | 1 | 2025 | 157 | 0.210 |
Why?
|
| Virus Integration | 3 | 2016 | 38 | 0.210 |
Why?
|
| Mutation | 5 | 2024 | 6196 | 0.210 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2015 | 37 | 0.210 |
Why?
|
| Disease Models, Animal | 5 | 2026 | 4682 | 0.210 |
Why?
|
| Recombinant Proteins | 6 | 2023 | 1318 | 0.200 |
Why?
|
| Automation, Laboratory | 1 | 2023 | 17 | 0.200 |
Why?
|
| HIV Integrase | 1 | 2022 | 3 | 0.190 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2022 | 16 | 0.190 |
Why?
|
| Microscopy | 1 | 2023 | 122 | 0.190 |
Why?
|
| HEK293 Cells | 4 | 2024 | 811 | 0.190 |
Why?
|
| CD4 Antigens | 1 | 2002 | 48 | 0.190 |
Why?
|
| High-Throughput Screening Assays | 1 | 2023 | 117 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 2 | 2023 | 153 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1418 | 0.180 |
Why?
|
| Viral Envelope Proteins | 4 | 2010 | 157 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2026 | 425 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 115 | 0.180 |
Why?
|
| Zika Virus Infection | 2 | 2020 | 178 | 0.170 |
Why?
|
| Genes, gag | 2 | 1998 | 8 | 0.170 |
Why?
|
| Receptors, CXCR3 | 1 | 2020 | 23 | 0.170 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 208 | 0.170 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 52 | 0.170 |
Why?
|
| Down-Regulation | 1 | 2002 | 659 | 0.160 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 15 | 0.160 |
Why?
|
| Lentiviruses, Primate | 1 | 2019 | 1 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2026 | 555 | 0.150 |
Why?
|
| Autophagy | 3 | 2022 | 424 | 0.150 |
Why?
|
| Deoxyribonucleotides | 1 | 2019 | 7 | 0.150 |
Why?
|
| DNA, Viral | 3 | 2026 | 452 | 0.150 |
Why?
|
| Mice | 12 | 2026 | 18368 | 0.150 |
Why?
|
| Rectum | 1 | 2020 | 103 | 0.150 |
Why?
|
| Machine Learning | 1 | 2023 | 375 | 0.150 |
Why?
|
| Macaca mulatta | 5 | 2023 | 497 | 0.150 |
Why?
|
| Antigenic Variation | 1 | 1999 | 37 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 382 | 0.150 |
Why?
|
| Gene Expression | 2 | 2021 | 1503 | 0.150 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 141 | 0.140 |
Why?
|
| Genes, env | 2 | 1997 | 9 | 0.140 |
Why?
|
| Receptors, Virus | 1 | 1999 | 97 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 798 | 0.140 |
Why?
|
| Interleukin-2 | 3 | 1998 | 237 | 0.140 |
Why?
|
| AIDS Vaccines | 1 | 2018 | 31 | 0.140 |
Why?
|
| Complement Factor I | 1 | 2017 | 1 | 0.140 |
Why?
|
| Complement C4b | 1 | 2017 | 5 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 344 | 0.130 |
Why?
|
| Camelids, New World | 1 | 2016 | 4 | 0.130 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2016 | 7 | 0.120 |
Why?
|
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2015 | 5 | 0.120 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 13 | 0.120 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2015 | 28 | 0.110 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 32 | 0.110 |
Why?
|
| Granzymes | 2 | 2014 | 47 | 0.110 |
Why?
|
| Cyclin T | 1 | 2015 | 31 | 0.110 |
Why?
|
| Recombinases | 1 | 2015 | 28 | 0.110 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2014 | 9 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2015 | 694 | 0.110 |
Why?
|
| Cyclins | 1 | 2015 | 94 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1994 | 125 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 260 | 0.110 |
Why?
|
| CD3 Complex | 1 | 1994 | 93 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 173 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 165 | 0.100 |
Why?
|
| Kinetics | 4 | 2019 | 1093 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2018 | 900 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 1746 | 0.100 |
Why?
|
| Jurkat Cells | 2 | 2007 | 85 | 0.100 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2012 | 2 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1261 | 0.090 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2016 | 49 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2016 | 693 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2010 | 589 | 0.090 |
Why?
|
| Blood Donors | 1 | 2012 | 56 | 0.090 |
Why?
|
| Retroviridae Proteins | 2 | 2007 | 10 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 4 | 1999 | 27 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 460 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1023 | 0.090 |
Why?
|
| Glycopeptides | 1 | 2011 | 26 | 0.090 |
Why?
|
| Binding Sites | 2 | 2004 | 1148 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 677 | 0.080 |
Why?
|
| Disease Progression | 3 | 2024 | 2226 | 0.080 |
Why?
|
| Neutralization Tests | 3 | 2024 | 226 | 0.080 |
Why?
|
| Protein Domains | 2 | 2021 | 248 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 86 | 0.080 |
Why?
|
| Virulence | 1 | 2010 | 273 | 0.080 |
Why?
|
| Gene Products, env | 3 | 2007 | 14 | 0.080 |
Why?
|
| Chimera | 3 | 1998 | 79 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 2011 | 787 | 0.080 |
Why?
|
| HTLV-I Antibodies | 1 | 1989 | 3 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2006 | 364 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1989 | 33 | 0.070 |
Why?
|
| Genotype | 2 | 2017 | 2652 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 1993 | 2573 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 102 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2010 | 748 | 0.070 |
Why?
|
| SAIDS Vaccines | 1 | 2007 | 12 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 793 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2011 | 1020 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 117 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1612 | 0.060 |
Why?
|
| Viremia | 1 | 2007 | 132 | 0.060 |
Why?
|
| Base Sequence | 4 | 2014 | 2783 | 0.060 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2006 | 31 | 0.060 |
Why?
|
| Male | 9 | 2023 | 65322 | 0.060 |
Why?
|
| Naphthols | 1 | 2026 | 11 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2012 | 519 | 0.060 |
Why?
|
| Indenes | 1 | 2025 | 11 | 0.060 |
Why?
|
| Haplorhini | 2 | 2020 | 106 | 0.060 |
Why?
|
| Drug Implants | 1 | 2025 | 41 | 0.060 |
Why?
|
| Furans | 1 | 2025 | 29 | 0.060 |
Why?
|
| Genes | 1 | 2006 | 308 | 0.060 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2025 | 34 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2025 | 121 | 0.060 |
Why?
|
| Benzamides | 1 | 2026 | 124 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2015 | 2442 | 0.060 |
Why?
|
| Alanine | 1 | 2025 | 162 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2001 | 622 | 0.060 |
Why?
|
| Adult | 6 | 2021 | 31716 | 0.060 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 129 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2012 | 987 | 0.050 |
Why?
|
| Apoptosis | 2 | 2022 | 1860 | 0.050 |
Why?
|
| CD2 Antigens | 2 | 1994 | 8 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2004 | 555 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1994 | 32 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2004 | 238 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 161 | 0.050 |
Why?
|
| Gene Products, gag | 2 | 2007 | 20 | 0.050 |
Why?
|
| Membrane Microdomains | 2 | 2016 | 60 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2025 | 296 | 0.050 |
Why?
|
| Female | 8 | 2025 | 71262 | 0.050 |
Why?
|
| DNA | 2 | 2006 | 1440 | 0.050 |
Why?
|
| Immunity | 1 | 2024 | 179 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 136 | 0.050 |
Why?
|
| Feedback | 1 | 2024 | 149 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 1994 | 126 | 0.050 |
Why?
|
| Raltegravir Potassium | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyrrolidinones | 1 | 2022 | 22 | 0.050 |
Why?
|
| Gene Products, nef | 1 | 2002 | 17 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 69 | 0.050 |
Why?
|
| Alum Compounds | 1 | 2022 | 41 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 18 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 986 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2022 | 161 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 215 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 123 | 0.040 |
Why?
|
| Lectins | 1 | 2001 | 50 | 0.040 |
Why?
|
| Virus Activation | 1 | 2022 | 86 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2022 | 112 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2018 | 772 | 0.040 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2021 | 38 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 5120 | 0.040 |
Why?
|
| Monocytes | 2 | 2006 | 337 | 0.040 |
Why?
|
| Genes, Viral | 2 | 1998 | 155 | 0.040 |
Why?
|
| Allergists | 1 | 2020 | 9 | 0.040 |
Why?
|
| Organophosphates | 1 | 2020 | 17 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 99 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 69 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2020 | 64 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 62 | 0.040 |
Why?
|
| RNA Transport | 1 | 2019 | 8 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 572 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 450 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 144 | 0.040 |
Why?
|
| Karyopherins | 1 | 2019 | 36 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3419 | 0.040 |
Why?
|
| Models, Immunological | 1 | 1999 | 37 | 0.040 |
Why?
|
| Primates | 1 | 2019 | 80 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 259 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2019 | 254 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 132 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 273 | 0.040 |
Why?
|
| Protein Transport | 1 | 2019 | 362 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 851 | 0.040 |
Why?
|
| Genes, pol | 1 | 1998 | 10 | 0.030 |
Why?
|
| Acute Disease | 2 | 2020 | 1153 | 0.030 |
Why?
|
| Americas | 1 | 2018 | 52 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2018 | 70 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2017 | 30 | 0.030 |
Why?
|
| Giant Cells | 1 | 1997 | 33 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 735 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 329 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 567 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 24 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 62 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Antibody Formation | 2 | 2008 | 232 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 47 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 609 | 0.030 |
Why?
|
| Transfection | 2 | 1998 | 960 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 312 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 817 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 282 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 792 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1999 | 752 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 985 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1997 | 358 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 533 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1673 | 0.030 |
Why?
|
| Genes, pX | 1 | 1995 | 4 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 1995 | 16 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2018 | 586 | 0.030 |
Why?
|
| Bone Marrow Stromal Antigen 2 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Stem Cells | 1 | 2020 | 713 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 1994 | 8 | 0.030 |
Why?
|
| United States | 1 | 2010 | 11825 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 57 | 0.030 |
Why?
|
| Evolution, Molecular | 2 | 2008 | 657 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 97 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 84 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 363 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2014 | 163 | 0.030 |
Why?
|
| CD58 Antigens | 1 | 1993 | 7 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2014 | 156 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2014 | 95 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2478 | 0.020 |
Why?
|
| Gene Products, tax | 1 | 1993 | 47 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 345 | 0.020 |
Why?
|
| Reverse Transcription | 1 | 2012 | 5 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2357 | 0.020 |
Why?
|
| Middle Aged | 4 | 2020 | 28894 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2010 | 17702 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 90 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 113 | 0.020 |
Why?
|
| Cell Division | 1 | 1993 | 720 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 208 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 96 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 419 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 162 | 0.020 |
Why?
|
| Fetal Blood | 1 | 1991 | 179 | 0.020 |
Why?
|
| Myristic Acids | 1 | 1989 | 6 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1989 | 17 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2014 | 726 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 719 | 0.020 |
Why?
|
| Hawaii | 1 | 1989 | 6 | 0.020 |
Why?
|
| Epitopes | 1 | 2010 | 328 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 694 | 0.020 |
Why?
|
| Deltaretrovirus Infections | 1 | 1988 | 7 | 0.020 |
Why?
|
| Glycosylation | 1 | 2008 | 124 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 4693 | 0.020 |
Why?
|
| Gene Products, pol | 1 | 2007 | 5 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2008 | 157 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 194 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 337 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2007 | 319 | 0.020 |
Why?
|
| Phylogeny | 1 | 2008 | 712 | 0.010 |
Why?
|
| Spleen | 1 | 2006 | 257 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 10104 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 275 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 21265 | 0.010 |
Why?
|
| Leukemia | 1 | 1988 | 375 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 542 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1236 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 468 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2001 | 68 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2001 | 20 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 2001 | 54 | 0.010 |
Why?
|
| Time Factors | 1 | 1991 | 6271 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 577 | 0.010 |
Why?
|
| Genome, Human | 1 | 2006 | 1338 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 530 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1989 | 6920 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 38 | 0.010 |
Why?
|
| DNA Probes | 1 | 1995 | 120 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1995 | 199 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 1219 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1995 | 2366 | 0.000 |
Why?
|
| Transfusion Reaction | 1 | 1988 | 41 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 4528 | 0.000 |
Why?
|